Vivaxin

Vivaxin is a prophylactic vaccine candidate designed to prevent malaria caused by the *Plasmodium vivax* parasite. It is primarily being developed to address malaria in regions where this species is endemic, such as Brazil. The vaccine consists of recombinant proteins administered via intramuscular injection, intended to stimulate a robust and protective immune response, specifically targeting the parasite to prevent clinical disease. In a separate biological context, "Vivaxin" (or Fam34) also refers to a large gene family in the parasite *Trypanosoma vivax*, which causes animal African trypanosomiasis (AAT). This gene family encodes transmembrane glycoproteins that are highly immunogenic and are under investigation as potential veterinary vaccine candidates.

Brand names

Vivaxin

Other names

Vivaxin vaccineVivaxin gene familyFam34Fam-34Fam 34